Alkermes (ALKS) vs Rhythm Pharmaceuticals (RYTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alkermes (ALKS) has outperformed Rhythm Pharmaceuticals (RYTM) over the past year, gaining 33.9% versus a loss of 11.4%. Over five years, RYTM leads with a +682.1% price change compared with +30.9% for ALKS. Alkermes is the larger company by market cap ($6.95 billion vs $6.09 billion), about 1.1 times the size, while Rhythm Pharmaceuticals is growing revenue faster (+45.8% vs -5.2%).
Alkermes converts more of its revenue into profit, with a net margin of 16.4% versus -103.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALKS | RYTM |
|---|---|---|
| Share price | $41.45 | $88.45 |
| Market cap | $6.95B | $6.09B |
| 1-day change | -0.49% | -2.56% |
| YTD return | +48.12% | -17.37% |
| 1-year return | +33.91% | -11.40% |
| 5-year return | +30.87% | +682.05% |
| P/E ratio (TTM) | 109.07 | — |
| Forward P/E | 22.92 | — |
| EPS (TTM) | $0.38 | $-3.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.48B | $189.76M |
| Revenue growth (YoY) | -5.25% | +45.83% |
| Net income (latest FY) | $241.66M | $-196.54M |
| Gross margin | 86.69% | 89.73% |
| Operating margin | 17.21% | -101.19% |
| Net margin | 16.37% | -103.57% |
| 52-week high | $55.67 | $122.20 |
| 52-week low | $27.00 | $74.50 |
| Distance from 52-week high | -25.55% | -27.62% |
| Analyst consensus | buy | none |
| Avg. price target upside | +36.47% | +56.69% |
| Average volume | 1.83M | 646.31K |
| Shares outstanding | 167.76M | 68.85M |
| Employees | 2,050 | 414 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALKS has outperformed RYTM by 45.3 percentage points over the past year.
- Alkermes is more profitable, keeping 16.4 cents of every revenue dollar as net income versus -103.6 cents for Rhythm Pharmaceuticals.
- Rhythm Pharmaceuticals grew revenue faster in its latest fiscal year (+45.83% vs -5.25%).
About Alkermes
ALKS stock →Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,050 employees
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
ALKS vs RYTM FAQ
Which is bigger, Alkermes or Rhythm Pharmaceuticals?
Alkermes (ALKS) is larger, with a market capitalization of $6.95B compared with $6.09B for Rhythm Pharmaceuticals (RYTM).
Which stock has performed better over the past year, ALKS or RYTM?
ALKS returned +33.91% over the past 12 months, compared with -11.40% for RYTM (price return, excluding dividends). Past performance does not predict future results.
Are Alkermes and Rhythm Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.